ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis says Cosentyx can potentially modify the course of psoriasis in certain patients
March 22, 2017Novartis on Tuesday unveiled data from a Phase III study suggesting that Cosentyx (secukinumab) can alter the course of moderate-to-severe psoriasis resulting in long-term, treatment-free skin clearance in some patients. -
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a tre
March 09, 2017Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin. -
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a tre
March 08, 2017Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin following relapse during a treatment pause. -
Phase 3 data for Janssen psoriasis drug shows efficacy over Humira
March 07, 2017Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of ... -
UCB, Dermira plan psoriasis filing for Cimzia in Q3
January 20, 2017UCB and Dermira are expecting to file anti-inflammatory Cimzia for psoriasis in the third quarter of this year, after the drug's strong performance in a late-stage trial involving patients with severe chronic plaque forms of the skin disease.
Pharma Sources Insight January 2025
